Watch the interview of Sharmila Joshi of Sharmilajoshi.com who shared her readings and outlook on specific stocks and sector & Harsh Roongta, Director of Apnapaisa.com answered few personal finance queries.
Below is the verbatim transcript of Sharmila Joshi's interview with CNBC-TV18:
I don’t think that many great things are going to happen for Oil and Natural Gas Corporation (ONGC) in the near-term. The way the crude prices have been falling is not a great positive for any company in the exploration space. Secondly, the overhanging worry part of which – you did hear some positive news that the subsidy burden sharing bit that there could be some relief for ONGC there. So, that could be the real thing that could sort of add the bright spot for ONGC in days to come because it doesn’t look like crude is going to recover in a hurry. So, one has to give at least a three to six months kind of outlook if one wants to stay in ONGC and if he/she is not willing to wait for about six months then should look to switch. I would recommend that one can switch to maybe an IT stock and buy a frontline stock like Tech Mahindra.
Tech Mahindra
One can hold Tech Mahindra because the kind of growth trajectory that I am expecting from Tech Mahindra in the next couple of years would give me a comfortable target of about Rs 3,200 for the stock. So given the way the business is poised and the kind of their verticals and the kind of the recent newsflow around the stock and possibilities going ahead, Rs 3,200 would be my target and I would stay invested.
Wockhardt
Within those three-four stocks that were introduced in F&O, Wockhardt would be the obvious choice for traders to go towards. For Wockhardt or for any pharmaceutical stock, the only negative can be some kind of newsflow from USFDA, some enquiry, some kind of comments. So I think that is the only caveat and we did see Wockhardt go through this whole series of bad news and fall and then recover from there but I don’t think anything has happened to justify the kind of move that we have seen from that Rs 800 levels to this Rs 1,000 levels except for the fact of being introduced in the F&O. With a year’s perspective, I think it is a decent stock but keep your ear to the ground for this kind of a negative newsflow not just for Wockhardt but for any pharmaceutical company and then stay invested, I would have one-year target of about Rs 1,200.
IDFC
IDFC is a company that finances infrastructure projects, so it is not a direct infrastructure play in that sense. Two year horizon for IDFC is fine because within that period, they will be able to leverage their niche position that they have within infrastructure financing and they will be able to take it to the next level given the fact that everybody is expecting infrastructure to be an area where a lot of financing is sort of going to be required. Secondly, I think there is that whole banking play which will sort of play out in the next couple of years, so from both those aspects, I think IDFC is a good stock with a two-year horizon.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
